CoChat
Cited by 203

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)

Open access
Cannon, Christopher P., McGuire, Darren K., Pratley, Richard, Dagogo-Jack, Sam, Mancuso, James, Huyck, Susan, Charbonnel, Bernard, Shih, Weichung J., Gallo, Silvina, Masiukiewicz, Urszula, Golm, Gregory, Cosentino, Francesco, Lauring, Brett, Terra, Steven G. · 2018 · American Heart Journal

Abstract

BACKGROUND: Ertugliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), approved in the United States and European Union to improve glycemic control in adults with type 2 diabetes mellitus (T2DM). The VERTIS cardiovascular (CV) outcomes trial (NCT01986881) has a primary objective to demonstrate non-inferiority of ertugliflozin versus placebo on major adverse CV events: time to the first event of CV death, nonfatal myocardial infarction, or nonfatal stroke. Secondary objectives are to demonstrate superiority of ertugliflozin versus placebo on time to: 1) the composite outcome of CV death or hospitalization for heart failure (HF); 2) CV death; and 3) the composite outcome of renal death, dialysis/transplant, or doubling of serum creatinine from baseline. METHODS: Patients ≥40 years old with T2DM (HbA1c 7.0-10.5%) and established atherosclerotic cardiovascular disease (ASCVD) of the coronary, cerebral, and/or peripheral arterial systems, were randomized 1:1:1 to once daily double-blind placebo, ertugliflozin 5 mg or 15 mg added to existing therapy. RESULTS: 8246 patients were randomized and 8238 received at least 1 dose of investigational product. Mean age was 64.4 years, 11.0% were ≥75 years old, and mean diabetes duration was 12.9 years with screening HbA1c of 8.3%. At entry, coronary artery disease, cerebrovascular disease, and peripheral arterial disease were present in 76.3%, 23.1%, and 18.8% of patients, respectively. HF was present in 23.1%, and Stage 3 kidney disease in 21.6% of patients. CONCLUSION: The results from the VERTIS-CV trial will define the CV and renal safety and efficacy of ertugliflozin in patients with T2DM and ASCVD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ahj.2018.08.016

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 14

  1. Roger, 2011, Heart disease and stroke statistics – 2011 update: a report from the American Heart Association, Circulation, 123, e18
  2. Raz, 2018, DECLARE-TIMI 58: Participants' baseline characteristics, Diabetes Obes Metab, 20, 1102, 10.1111/dom.13217 · DOI
  3. Terra, 2017, Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone, Diabetes Obes Metab, 19, 721, 10.1111/dom.12888 · DOI
  4. Rosenstock, 2018, Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET), Diabetes Obes Metab, 20, 520, 10.1111/dom.13103 · DOI · Paper page
  5. Dagogo-Jack, 2018, Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study, Diabetes Obes Metab, 20, 530, 10.1111/dom.13116 · DOI
  6. Hollander, 2018, Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: the VERTIS SU randomized study, Diabetes Ther, 9, 193, 10.1007/s13300-017-0354-4 · DOI
  7. Pratley, 2018, Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial, Diabetes Obes Metab, 20, 1111, 10.1111/dom.13194 · DOI · Paper page
  8. Zinman, 2014, Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™), Cardiovasc Diabetol, 13, 102, 10.1186/1475-2840-13-102 · DOI · Paper page
  9. Neal, 2017, Optimizing the analysis strategy for the CANVAS program: a prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials, Diabetes Obes Metab, 19, 926, 10.1111/dom.12924 · DOI
  10. Bhatt, 2006, Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events, N Engl J Med, 354, 1706, 10.1056/NEJMoa060989 · DOI · Paper page
  11. McMurray, 2014, Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored, Lancet Diabetes Endocrinol, 2, 843, 10.1016/S2213-8587(14)70031-2 · DOI · Paper page
  12. Gilbert, 2015, Heart failure in diabetes: effects on anti-hyperglycaemic drug therapy, Lancet, 385, 2107, 10.1016/S0140-6736(14)61402-1 · DOI · Paper page
  13. Marx, 2016, Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus, Eur Heart J, 37, 3192, 10.1093/eurheartj/ehw110 · DOI · Paper page
  14. Taegtmeyer, 2016, Failing heart and starving brain: ketone bodies to the rescue, Circulation, 134, 265, 10.1161/CIRCULATIONAHA.116.022141 · DOI

Cited by

See all 203

Metadata

Authors
Cannon, C. P., McGuire, D. K., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Charbonnel, B., Shih, W. J., Gallo, S., Masiukiewicz, U., Golm, G., Cosentino, F., Lauring, B., & Terra, S. G.
Venue
American Heart Journal
Publisher
Elsevier BV
Published
2018-12
Volume
206
Pages
11-23
ISSN
0002-8703 (ISSN-L)
OpenAlex
W2890465901
Cited by
203
References
14
FWCI
26.44
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
  • Merck Sharp and Dohme
  • Pfizer
  • Merck

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). https://app.cochat.ai/papers/10.1016/j.ahj.2018.08.016
The paper
Cannon, C. P., McGuire, D. K., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Charbonnel, B., Shih, W. J., Gallo, S., Masiukiewicz, U., Golm, G., Cosentino, F., Lauring, B., & Terra, S. G. (2018). Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). American Heart Journal. https://doi.org/10.1016/j.ahj.2018.08.016

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.